Thrombosis research最新文献

英文中文

IgM-enriched immunoglobulin treatment significantly improves coagulation dysbalance in an experimental animal model of fulminant sepsis. 在暴发性败血症的实验动物模型中，igm富集免疫球蛋白治疗可显著改善凝血失衡。

IF 3.4 3区医学 Q1 HEMATOLOGY

Thrombosis research

Pub Date : 2026-02-05 DOI: 10.1016/j.thromres.2026.109607

Ildikó Beke Debreceni, Bálint Krajcsir, Ádám Attila Mátrai, Balázs Ujhelyi, Marianna Pócsi, György Jázon Balla, Béla Nagy, Ádám Deák, Norbert Németh, Béla Fülesdi, János Kappelmayer

Introduction: Inflammation and coagulation are closely interrelated process in the pathogenesis of sepsis. In this study, we investigated whether intravenous IgM-enriched immunoglobulin (IgM-IVIG) preparation could improve hemostatic abnormalities in a fulminant sepsis model.

Materials and methods: Live Escherichia coli (E.coli) bacteria were administered to pigs with simultaneously (E. coli + Ig) or delayed (E. coli post Ig) of IgM-IVIG while control pigs received only physiological saline. Prothrombin time, activated partial thromboplastin time (APTT) and fibrinogen were measured by coagulometry. Hematologic parameters and soluble P-selectin were also measured. Furthermore, thrombin generation assay was carried out by fluorimetry and results were evaluated by the Thrombinoscope software.

Results: In septic pigs continous increase of fibrinogen levels and significant prolongation of APTT were observed. However, IgM-IVIG treatment significantly decreased fibrinogen levels and shortened the APTT after E. coli administration. In addition, in thrombin generation assay (TGA), that was performed without any exogenous coagulation trigger a significant increase of endogenous thrombin potential (ETP) and peak thrombin were observed in the E. coli-administered group which were abolished by IgM-IVIG treatment. Furthermore, in another TGA using phospholipid and tissue factor triggers, a significant decrease of ETP and thrombin peak were detected in septic-group, however IgM-IVIG treatment prevented the effect of E. coli. Increased level of soluble P-selectin was measured in E. coli-administered group, but it was attenuted by simultaneously administered IgM-IVIG treatment.

Conclusions: We conclude that IgM-IVIG attenuates sepsis-induced hemostatic abnormalities, and the effect of simultaneously administered IgM-IVIG was more pronounced.

在脓毒症的发病过程中，炎症与凝血是密切相关的过程。在这项研究中，我们研究了静脉注射igm富集免疫球蛋白（IgM-IVIG）制剂是否可以改善暴发性脓毒症模型中的止血异常。材料与方法：将活的大肠杆菌（E.coli）同时（E.coli + Ig）或延迟（E.coli后Ig）注射IgM-IVIG，对照组只注射生理盐水。采用凝血法测定凝血酶原时间、活化部分凝血活酶时间（APTT）和纤维蛋白原。测定血液学参数和可溶性p选择素。此外，通过荧光法进行凝血酶生成测定，并通过凝血镜软件评估结果。结果：脓毒症猪纤维蛋白原水平持续升高，APTT明显延长。然而，IgM-IVIG治疗显著降低纤维蛋白原水平，缩短大肠杆菌给药后的APTT。此外，在没有任何外源性凝血触发的情况下进行的凝血酶生成试验（TGA）中，观察到大肠杆菌给药组内源性凝血酶电位（ETP）和凝血酶峰值显著增加，而IgM-IVIG治疗使其消失。此外，在另一种使用磷脂和组织因子触发的TGA中，败血症组的ETP和凝血酶峰值显著降低，而IgM-IVIG治疗阻止了大肠杆菌的影响。大肠杆菌组可溶性p选择素水平升高，但同时给予IgM-IVIG处理可使其降低。结论：IgM-IVIG可减轻败血症引起的止血异常，且同时给予IgM-IVIG的效果更为明显。

{"title":"IgM-enriched immunoglobulin treatment significantly improves coagulation dysbalance in an experimental animal model of fulminant sepsis.","authors":"Ildikó Beke Debreceni, Bálint Krajcsir, Ádám Attila Mátrai, Balázs Ujhelyi, Marianna Pócsi, György Jázon Balla, Béla Nagy, Ádám Deák, Norbert Németh, Béla Fülesdi, János Kappelmayer","doi":"10.1016/j.thromres.2026.109607","DOIUrl":"https://doi.org/10.1016/j.thromres.2026.109607","url":null,"abstract":"<p><strong>Introduction: </strong>Inflammation and coagulation are closely interrelated process in the pathogenesis of sepsis. In this study, we investigated whether intravenous IgM-enriched immunoglobulin (IgM-IVIG) preparation could improve hemostatic abnormalities in a fulminant sepsis model.</p><p><strong>Materials and methods: </strong>Live Escherichia coli (E.coli) bacteria were administered to pigs with simultaneously (E. coli + Ig) or delayed (E. coli post Ig) of IgM-IVIG while control pigs received only physiological saline. Prothrombin time, activated partial thromboplastin time (APTT) and fibrinogen were measured by coagulometry. Hematologic parameters and soluble P-selectin were also measured. Furthermore, thrombin generation assay was carried out by fluorimetry and results were evaluated by the Thrombinoscope software.</p><p><strong>Results: </strong>In septic pigs continous increase of fibrinogen levels and significant prolongation of APTT were observed. However, IgM-IVIG treatment significantly decreased fibrinogen levels and shortened the APTT after E. coli administration. In addition, in thrombin generation assay (TGA), that was performed without any exogenous coagulation trigger a significant increase of endogenous thrombin potential (ETP) and peak thrombin were observed in the E. coli-administered group which were abolished by IgM-IVIG treatment. Furthermore, in another TGA using phospholipid and tissue factor triggers, a significant decrease of ETP and thrombin peak were detected in septic-group, however IgM-IVIG treatment prevented the effect of E. coli. Increased level of soluble P-selectin was measured in E. coli-administered group, but it was attenuted by simultaneously administered IgM-IVIG treatment.</p><p><strong>Conclusions: </strong>We conclude that IgM-IVIG attenuates sepsis-induced hemostatic abnormalities, and the effect of simultaneously administered IgM-IVIG was more pronounced.</p>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"259 ","pages":"109607"},"PeriodicalIF":3.4,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Venous thromboembolism prevention in ambulatory oncology: A multi-method evaluation of the Vermont Model to inform adaptation to an oncology-delivered model. 静脉血栓栓塞预防在门诊肿瘤学：佛蒙特模型的多方法评估，以告知适应肿瘤学交付模型。

IF 3.4 3区医学 Q1 HEMATOLOGY

Thrombosis research

Pub Date : 2026-02-04 DOI: 10.1016/j.thromres.2026.109610

Karlyn A Martin, Emily Hallgren, Chris E Holmes, Jacob Barker, Lisa R Hirschhorn, Kenzie A Cameron

Background: Despite evidence-based guidelines, venous thromboembolism (VTE) prevention in ambulatory cancer remains low. The "Vermont Model" is a multidisciplinary program wherein oncology nurses conduct VTE risk assessment, VTE patient-education to all patients starting anti-cancer therapy and refer high risk patients to thrombosis specialist to discuss thromboprophylaxis. The Vermont Model successfully improved targeted anticoagulation prophylaxis for high-risk patients, but efforts to reproduce the model in community oncology practices were less successful. The objective of this study was to evaluate stakeholder (clinician and patient) perceptions of the Vermont Model to inform adaptation to a fully oncology-delivered approach.

Methods: We conducted a concurrent multi-method study from September 2024-January 2025, including a clinician survey assessing normalizing of the Vermont Model into clinical practice and semi-structured interviews of participating clinicians and patients.

Results: Ten clinicians and four patients completed interviews. Based on 9 clinician surveys, the Vermont Model is normalized into practice. Factors important to its success reflected in both the survey and interviews data included a strong culture valuing VTE prevention and a local champion. Participants supported a fully oncology-delivered model, yet challenges to success include lapses in intervention education/training, communication among health care team, and relative priority with existing workload.

Conclusion: We found high normalization of the Vermont Model among participating clinicians and highlight opportunities to enhance training, education, and interprofessional communication to scale out to a fully oncology-delivered model.

背景：尽管有循证指南，静脉血栓栓塞（VTE）预防在门诊癌症仍然很低。“佛蒙特模式”是一个多学科项目，肿瘤学护士对所有开始抗癌治疗的患者进行静脉血栓栓塞风险评估、静脉血栓栓塞患者教育，并将高危患者转诊给血栓专科医生讨论血栓预防。佛蒙特模型成功地改善了高危患者的靶向抗凝预防，但在社区肿瘤学实践中复制该模型的努力却不太成功。本研究的目的是评估利益相关者（临床医生和患者）对佛蒙特模式的看法，以告知适应完全肿瘤学交付的方法。方法：从2024年9月至2025年1月，我们进行了一项多方法并行研究，包括评估佛蒙特模型在临床实践中的正常化的临床医生调查，以及参与临床医生和患者的半结构化访谈。结果：10名临床医生和4名患者完成了访谈。基于对9名临床医生的调查，佛蒙特模型被规范化到实践中。在调查和访谈数据中反映的对其成功的重要因素包括重视静脉血栓栓塞预防的强大文化和当地的冠军。参与者支持完全由肿瘤学提供的模式，但成功的挑战包括干预教育/培训的缺失、卫生保健团队之间的沟通以及现有工作量的相对优先级。结论：我们发现在参与的临床医生中，佛蒙特模式高度规范化，并强调了加强培训、教育和跨专业沟通的机会，以扩展到完全的肿瘤交付模式。

{"title":"Venous thromboembolism prevention in ambulatory oncology: A multi-method evaluation of the Vermont Model to inform adaptation to an oncology-delivered model.","authors":"Karlyn A Martin, Emily Hallgren, Chris E Holmes, Jacob Barker, Lisa R Hirschhorn, Kenzie A Cameron","doi":"10.1016/j.thromres.2026.109610","DOIUrl":"https://doi.org/10.1016/j.thromres.2026.109610","url":null,"abstract":"<p><strong>Background: </strong>Despite evidence-based guidelines, venous thromboembolism (VTE) prevention in ambulatory cancer remains low. The \"Vermont Model\" is a multidisciplinary program wherein oncology nurses conduct VTE risk assessment, VTE patient-education to all patients starting anti-cancer therapy and refer high risk patients to thrombosis specialist to discuss thromboprophylaxis. The Vermont Model successfully improved targeted anticoagulation prophylaxis for high-risk patients, but efforts to reproduce the model in community oncology practices were less successful. The objective of this study was to evaluate stakeholder (clinician and patient) perceptions of the Vermont Model to inform adaptation to a fully oncology-delivered approach.</p><p><strong>Methods: </strong>We conducted a concurrent multi-method study from September 2024-January 2025, including a clinician survey assessing normalizing of the Vermont Model into clinical practice and semi-structured interviews of participating clinicians and patients.</p><p><strong>Results: </strong>Ten clinicians and four patients completed interviews. Based on 9 clinician surveys, the Vermont Model is normalized into practice. Factors important to its success reflected in both the survey and interviews data included a strong culture valuing VTE prevention and a local champion. Participants supported a fully oncology-delivered model, yet challenges to success include lapses in intervention education/training, communication among health care team, and relative priority with existing workload.</p><p><strong>Conclusion: </strong>We found high normalization of the Vermont Model among participating clinicians and highlight opportunities to enhance training, education, and interprofessional communication to scale out to a fully oncology-delivered model.</p>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"259 ","pages":"109610"},"PeriodicalIF":3.4,"publicationDate":"2026-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Simplifying the next-generation of anticoagulants: Elexians - Why a unified nomenclature for FXI/Xia inhibitors is needed. 简化下一代抗凝血剂：Elexians -为什么需要FXI/Xia抑制剂的统一命名

IF 3.4 3区医学 Q1 HEMATOLOGY

Thrombosis research

Pub Date : 2026-02-01 DOI: 10.1016/j.thromres.2026.109608

Andaleb Kholmukhamedov

引用次数: 0

Monitoring the Hemostatic Balance: measuring thrombin generation in a patient with acquired hemophilia A on combined pro- and anticoagulant therapy. 监测止血平衡：测量获得性血友病a患者在抗凝和促凝联合治疗中的凝血酶生成。

IF 3.4 3区医学 Q1 HEMATOLOGY

Thrombosis research

Pub Date : 2026-01-31 DOI: 10.1016/j.thromres.2026.109604

Marieke J A Verhagen, Saskia E M Schols, Sanna R Rijpma, An K Stroobants

引用次数: 0

Corrigendum to "Real-world safety and effectiveness of rurioctocog alfa pegol in 338 patients with hemophilia A in South Korea: A postmarketing surveillance study" [Thromb. Res. 253 (2025) 109402]. 对韩国338例A型血友病患者ruurioctocog alfa pegol的实际安全性和有效性的更正：一项上市后监测研究[Thromb]。第253（2025）条[9402]。

IF 3.4 3区医学 Q1 HEMATOLOGY

Thrombosis research

Pub Date : 2026-01-30 DOI: 10.1016/j.thromres.2026.109586

Ji Yoon Kim, Taiju Hwang, Sang Kyu Park, Ki-Young Yoo, Eun Jin Choi, Soyon Kim, Chur Woo You, Eungsun Kim, Aeran Jung, Young-Shil Park

引用次数: 0

The distinct etiology and imaging features of pediatric pulmonary embolism: dominance of Mycoplasma pneumoniae-associated in-situ thrombosis and severity risk stratification 儿童肺栓塞的独特病因学和影像学特征：肺炎支原体相关原位血栓形成的优势和严重程度风险分层

IF 3.4 3区医学 Q1 HEMATOLOGY

Thrombosis research

Pub Date : 2026-01-27 DOI: 10.1016/j.thromres.2026.109597

Ruxuan He , Xiaoyan Zhang , Xiaolei Tang , Yuelin Shen , Hui Liu , Jinrong Liu , Huimin Li , Shunying zhao , Haiming Yang

Background

Pediatric pulmonary embolism (PE) incidence has shown a steady rise in recent years, underscoring a distinct and evolving etiological landscape. Infection-related PE, notably Mycoplasma pneumoniae (MPP), now accounts for an increasing proportion of pediatric PE cases, raising questions about a distinct in-situ thrombosis (ISPAT) pathophysiology. We aimed to systematically characterize the etiological spectrum of childhood PE and identify independent predictors of severe disease.

Methods

We conducted a 6-year retrospective cohort study of 113 pediatric PE pediatric patients diagnosed with PE at Department No.2 of Respiratory Medicine, Beijing Children's Hospital, from June 2018 to June 2024. Data included clinical and imaging findings, underlying conditions, and outcomes. Predictors of severe PE were assessed using multivariable logistic regression.

Results

The median age was 8.37 years. Infection was the leading etiology (89.4%), most commonly MPP (88.1%). Computed tomography pulmonary angiography (CTPA) revealed emboli were predominantly subsegmental/peripheral (80.5%), supporting the ISPAT phenotype. Post-infectious pulmonary vasculitis was identified in 8 patients, with NOD2, MPEG1, or CYBB variants detected in 3 cases. On multivariable analysis, infection−associated PE was independently linked to lower odds of severe PE (adjusted OR 0.12, 95% CI 0.03–0.54; p = 0.0055).

Conclusion

Pediatric PE is predominantly an ISPAT phenomenon driven by MPP-associated immunothrombosis. The distinct thrombotic pattern and better prognosis in the infection group support etiology based risk stratification. Furthermore, the observed links with post-infectious vasculitis and variants in NOD2, MPEG1, or CYBB suggest that occult immune dysregulation may modulate thrombotic risk in susceptible children.

近年来，儿童肺栓塞（PE）的发病率稳步上升，强调了一个独特的和不断变化的病因学格局。感染相关的PE，特别是肺炎支原体（MPP），现在在儿科PE病例中所占的比例越来越大，这引起了对独特的原位血栓形成（ISPAT）病理生理学的质疑。我们的目的是系统地描述儿童PE的病因谱，并确定严重疾病的独立预测因素。方法对2018年6月至2024年6月在北京儿童医院呼吸医学二科诊断为PE的113例儿科PE患儿进行6年回顾性队列研究。数据包括临床和影像学表现、基础条件和结果。使用多变量逻辑回归评估严重PE的预测因素。结果患者中位年龄为8.37岁。感染是主要病因（89.4%），最常见的是MPP（88.1%）。ct肺血管造影（CTPA）显示栓塞主要为亚节段性/外周性（80.5%），支持ISPAT表型。8例患者发现感染后肺血管炎，3例检测到NOD2、MPEG1或CYBB变异。在多变量分析中，感染相关的PE与较低的严重PE发生率独立相关（调整后OR 0.12, 95% CI 0.03-0.54; p = 0.0055）。结论小儿PE主要是由mpp相关免疫血栓形成所致的ISPAT现象。感染组明显的血栓形成模式和较好的预后支持基于病因学的危险分层。此外，观察到的与感染后血管炎和NOD2、MPEG1或CYBB变异的联系表明，隐性免疫失调可能会调节易感儿童的血栓形成风险。

{"title":"The distinct etiology and imaging features of pediatric pulmonary embolism: dominance of Mycoplasma pneumoniae-associated in-situ thrombosis and severity risk stratification","authors":"Ruxuan He , Xiaoyan Zhang , Xiaolei Tang , Yuelin Shen , Hui Liu , Jinrong Liu , Huimin Li , Shunying zhao , Haiming Yang","doi":"10.1016/j.thromres.2026.109597","DOIUrl":"10.1016/j.thromres.2026.109597","url":null,"abstract":"<div><h3>Background</h3><div>Pediatric pulmonary embolism (PE) incidence has shown a steady rise in recent years, underscoring a distinct and evolving etiological landscape. Infection-related PE, notably <em>Mycoplasma pneumoniae</em> (MPP), now accounts for an increasing proportion of pediatric PE cases, raising questions about a distinct in-situ thrombosis (ISPAT) pathophysiology. We aimed to systematically characterize the etiological spectrum of childhood PE and identify independent predictors of severe disease.</div></div><div><h3>Methods</h3><div>We conducted a 6-year retrospective cohort study of 113 pediatric PE pediatric patients diagnosed with PE at Department No.2 of Respiratory Medicine, Beijing Children's Hospital, from June 2018 to June 2024. Data included clinical and imaging findings, underlying conditions, and outcomes. Predictors of severe PE were assessed using multivariable logistic regression.</div></div><div><h3>Results</h3><div>The median age was 8.37 years. Infection was the leading etiology (89.4%), most commonly MPP (88.1%). Computed tomography pulmonary angiography (CTPA) revealed emboli were predominantly subsegmental/peripheral (80.5%), supporting the ISPAT phenotype. Post-infectious pulmonary vasculitis was identified in 8 patients, with NOD2, MPEG1, or CYBB variants detected in 3 cases. On multivariable analysis, infection−associated PE was independently linked to lower odds of severe PE (adjusted OR 0.12, 95% CI 0.03–0.54; <em>p</em> = 0.0055).</div></div><div><h3>Conclusion</h3><div>Pediatric PE is predominantly an ISPAT phenomenon driven by MPP-associated immunothrombosis. The distinct thrombotic pattern and better prognosis in the infection group support etiology based risk stratification. Furthermore, the observed links with post-infectious vasculitis and variants in NOD2, MPEG1, or CYBB suggest that occult immune dysregulation may modulate thrombotic risk in susceptible children.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"259 ","pages":"Article 109597"},"PeriodicalIF":3.4,"publicationDate":"2026-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146057466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letter in reference to the recent article: “Absorption and anticoagulant management of rivaroxaban in patients with short bowel syndrome” by Lunau et al. 参考Lunau等人最近发表的文章：“利伐沙班在短肠综合征患者中的吸收和抗凝管理”。

IF 3.4 3区医学 Q1 HEMATOLOGY

Thrombosis research

Pub Date : 2026-01-23 DOI: 10.1016/j.thromres.2026.109596

Danica Michaličková , Karolína Hronová

引用次数: 0

Monocyte depletion reduces late experimental post-thrombotic fibrotic injury in a stasis mouse model 单核细胞耗竭减少实验性晚期血栓后纤维化损伤在停滞小鼠模型

IF 3.4 3区医学 Q1 HEMATOLOGY

Thrombosis research

Pub Date : 2026-01-22 DOI: 10.1016/j.thromres.2026.109595

Mattea Pellerito , Abigail R. Dowling , Catherine E. Luke , Qing Cai , Antonio M. Pellerito , Andrew Quang , Lonnie Shea , Farouc Jaffer , Andrea Obi , Peter K. Henke

Background

Post thrombotic syndrome is a fibrotic disease related to inflammation resolution. There are no direct therapies that can ameliorate this disease. Monocyte/macrophages (Mo/MØ) are the primary leukocyte involved with later venous resolution, and likely direct vein wall responses and healing. Herein, we explored the vein wall response with Mo/MØ depletion by two methods.

Methods

Using two mouse models of venous thrombosis (VT), complete stasis and a flow restricted model, Mo/MØ depletion was accomplished using CD11b-DTR mice administered diphtheria toxin, and clodronate micelle administration in wild type mice. Tissue assays for structural histology, immunohistochemistry and western blotting were performed.

Results

Mo/MØ depletion resulted in significantly less vein wall fibrotic thickness, in the stasis model at day 14 in both the CD11b-DTR mice and those receiving clodronate micelles. No significant effect of Mo/MØ depletion was observed in the flow restricted VT model. The decrease in vein wall fibrosis was associated with fewer DDR2+ vein wall cells in the CD11b-DTR mice, but no difference in endothelial luminal coverage. Decreased cytokine and growth factor expression of IL-6, FSP-1, and VEGFa were associated with Mo/MØ depletion. Lastly, PMN depletion was associated with increased proinflammatory Mo/MØ, and a trend towards increased vein wall fibrosis as compared with controls.

Conclusion

Mo/MØ direct the post VT late fibrotic response, possibly by affecting fibroblasts and inflammatory cytokine expression. This effect was only found with the complete stasis model and is consistent with worsened PTS in humans with complete venous obstruction.

背景：血栓形成后综合征是一种与炎症消退相关的纤维化疾病。目前还没有直接的治疗方法可以改善这种疾病。单核细胞/巨噬细胞（Mo/MØ）是参与后期静脉溶解的主要白细胞，可能直接静脉壁反应和愈合。在此，我们通过两种方法探讨了Mo/MØ耗尽时的静脉壁响应。方法采用两种小鼠静脉血栓形成模型、完全停滞模型和血流受限模型，采用CD11b-DTR小鼠给予白喉毒素和氯膦酸盐胶束给予野生型小鼠，完成Mo/MØ的消耗。进行组织结构组织学、免疫组织化学和免疫印迹分析。结果smo /MØ缺失导致CD11b-DTR小鼠和接受氯膦酸胶束治疗的小鼠在第14天的停滞模型中静脉壁纤维化厚度明显减少。在受限流动的VT模型中未观察到Mo/MØ消耗的显著影响。在CD11b-DTR小鼠中，静脉壁纤维化的减少与较少的DDR2+静脉壁细胞有关，但内皮管腔覆盖没有差异。细胞因子和生长因子IL-6、FSP-1和VEGFa表达的降低与Mo/MØ缺失有关。最后，与对照组相比，PMN消耗与促炎Mo/MØ增加以及静脉壁纤维化增加的趋势相关。结论mo /MØ可能通过影响成纤维细胞和炎性细胞因子的表达，直接影响VT后晚期纤维化反应。这种影响仅在完全停滞模型中发现，并且与完全性静脉阻塞患者PTS恶化一致。

{"title":"Monocyte depletion reduces late experimental post-thrombotic fibrotic injury in a stasis mouse model","authors":"Mattea Pellerito , Abigail R. Dowling , Catherine E. Luke , Qing Cai , Antonio M. Pellerito , Andrew Quang , Lonnie Shea , Farouc Jaffer , Andrea Obi , Peter K. Henke","doi":"10.1016/j.thromres.2026.109595","DOIUrl":"10.1016/j.thromres.2026.109595","url":null,"abstract":"<div><h3>Background</h3><div>Post thrombotic syndrome is a fibrotic disease related to inflammation resolution. There are no direct therapies that can ameliorate this disease. Monocyte/macrophages (Mo/MØ) are the primary leukocyte involved with later venous resolution, and likely direct vein wall responses and healing. Herein, we explored the vein wall response with Mo/MØ depletion by two methods.</div></div><div><h3>Methods</h3><div>Using two mouse models of venous thrombosis (VT), complete stasis and a flow restricted model, Mo/MØ depletion was accomplished using CD11b-DTR mice administered diphtheria toxin, and clodronate micelle administration in wild type mice. Tissue assays for structural histology, immunohistochemistry and western blotting were performed.</div></div><div><h3>Results</h3><div>Mo/MØ depletion resulted in significantly less vein wall fibrotic thickness, in the stasis model at day 14 in both the CD11b-DTR mice and those receiving clodronate micelles. No significant effect of Mo/MØ depletion was observed in the flow restricted VT model. The decrease in vein wall fibrosis was associated with fewer DDR2+ vein wall cells in the CD11b-DTR mice, but no difference in endothelial luminal coverage. Decreased cytokine and growth factor expression of IL-6, FSP-1, and VEGFa were associated with Mo/MØ depletion. Lastly, PMN depletion was associated with increased proinflammatory Mo/MØ, and a trend towards increased vein wall fibrosis as compared with controls.</div></div><div><h3>Conclusion</h3><div>Mo/MØ direct the post VT late fibrotic response, possibly by affecting fibroblasts and inflammatory cytokine expression. This effect was only found with the complete stasis model and is consistent with worsened PTS in humans with complete venous obstruction.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"259 ","pages":"Article 109595"},"PeriodicalIF":3.4,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146057467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mild hemophilia B in a female with compound heterozygous FIX variants presented with abdominal pain and diagnosed with nutcracker syndrome, and median arcuate ligament syndrome 一名患有复合杂合FIX变异的女性患有轻度血友病B，表现为腹痛，诊断为胡桃钳综合征和正中弓状韧带综合征

IF 3.4 3区医学 Q1 HEMATOLOGY

Thrombosis research

Pub Date : 2026-01-20 DOI: 10.1016/j.thromres.2026.109594

Davut Ünsal Çapkan , Asmin Çelik , Uğur Gümüş , İbrahim Tayfun Şahiner , Ekrem Ünal

引用次数: 0

Automated thrombin generation assay in patients entering hospital for total hip or knee arthroplasty: A prospective study 全髋关节或膝关节置换术患者自动凝血酶生成测定：一项前瞻性研究。

IF 3.4 3区医学 Q1 HEMATOLOGY

Thrombosis research

Pub Date : 2026-01-19 DOI: 10.1016/j.thromres.2026.109591

Mathias Chea , Eva Nouvellon , Sandrine Alonso , Philippe Marchand , Rémy Coulomb , Pascal Kouyoumdjian , Mikaël Perin , Jeremy Laurent , Thibault Mura , Antonia Perez-Martin , Sylvie Bouvier , Jean-Christophe Gris

引用次数: 0

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Thrombosis research

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀